Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Thorac Cardiovasc Surg ; 60(4): 305-6, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21452115

ABSTRACT

Glomus tumors, also known as paragangliomas or chemodectomas, arise from well-differentiated mesenchymal cells that are known to be benign. These tumors account for 2% of all soft tissue tumors. The first case of a cardiac glomus tumor was reported in 1924 by Masson.1 Glomus tumors located within the pericardial tissue are extremely rare. We present the case of a recurrent cardiac glomus tumor. The preoperative investigation, diagnostic problems and surgical treatment of this case will be highlighted. Moreover we wish to emphasize the importance of such an entity and to remind readers that it must be included in the differential diagnosis of a pericardial tumor.


Subject(s)
Cardiac Surgical Procedures , Glomus Tumor/surgery , Heart Neoplasms/surgery , Neoplasm Recurrence, Local , Female , Glomus Tumor/pathology , Heart Neoplasms/pathology , Humans , Middle Aged , Reoperation , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
2.
J Cardiovasc Surg (Torino) ; 52(3): 399-409, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21577194

ABSTRACT

AIM: After cardioplegia and subsequent reperfusion of the myocardium as employed in cardiac surgery, ischemia/reperfusion injury of the myocardium can induce apoptosis. The aim of this study was to evaluate the anti-apoptotic properties of resveratrol, a phenolic phytoalexin present in grape skins and especially red wines during simulated cardioplegia (cp) and reperfusion (rep) in an in-vitro microperfusion model on human myocardium, which to our knowledge has not been investigated yet. METHODS: Cardiac specimens were retrieved from the right auricle of patients undergoing elective coronary artery bypass graft before induction of cardiopulmonary bypass. Cardiac specimens, with resveratrol (10 µM) (N.=15) and w/o resveratrol (control, N.=15) were exposed in vitro to varying periods of cp/rep (30/10, 60/20, 120/40 min) in a microperfusion chamber. For detection of apoptosis anti-activated-caspase-3, PARP-1 cleavage immunostaining and real-time PCR for gene expression of cardiac cytokines like BNP, NF-κB1, NF-κB2, E-Selectin, Troponin and TNF-α were employed. CONTROL GROUP: the longer the cp/rep period lasted the higher were the rate of anti-activated-caspase-3 positive cardiomyocytes (21.26±2.07% ­ 46.56±3.2%) and of PARP1-cleavage positive cardiomyocytes (23.29±2.16% ­ 36.86±2.11%). Resveratrol group: apoptosis was suppressed significantly (P<0.05). Anti-activated-caspase-3 positive cardiomyocytes (13.45±4.35% ­ 15.3±2.97%) and PARP1-cleavage positive cardiomyocytes (9.87±2.04% ­ 11.77±3.42%). Resveratrol significantly suppressed the expression of BNP, NF-κB2, E-Selectin, Troponin and TNF-α in vitro (P<0.05). CONCLUSION: Resveratrol significantly suppresses apoptosis under our applied in vitro conditions. This finding warrants further studies aiming suppression of ischemia/reperfusion injury in clinical settings.


Subject(s)
Apoptosis/drug effects , Extracorporeal Circulation/adverse effects , Heart Arrest, Induced/adverse effects , Myocardial Reperfusion Injury/prevention & control , Myocytes, Cardiac/drug effects , Protective Agents/pharmacology , Stilbenes/pharmacology , Aged , Biopsy , Caspase 3/metabolism , Cytokines/genetics , Cytokines/metabolism , Female , Gene Expression Regulation , Humans , Immunohistochemistry , In Vitro Techniques , Male , Middle Aged , Myocardial Reperfusion Injury/enzymology , Myocardial Reperfusion Injury/etiology , Myocardial Reperfusion Injury/pathology , Myocytes, Cardiac/enzymology , Myocytes, Cardiac/pathology , Perfusion , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Resveratrol , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
3.
Thorac Cardiovasc Surg ; 59(7): 439-41, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21445826

ABSTRACT

Coronary artery aneurysms (CAA) in adults are rare. However, the natural history of CAA is unknown since in adults it is predominantly atherosclerotic in origin. The clinical presentation, prognosis and management of giant CAA are not well defined due to limited experience and the low incidence of CAA. We present a case of successful exclusion of multiple giant CAA with an interposed reversed saphenous vein graft.


Subject(s)
Coronary Aneurysm/surgery , Coronary Artery Bypass , Saphenous Vein/transplantation , Aged , Coronary Aneurysm/diagnostic imaging , Coronary Angiography , Humans , Male , Tomography, X-Ray Computed , Treatment Outcome
4.
Thorac Cardiovasc Surg ; 58(5): 285-90, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20680905

ABSTRACT

BACKGROUND: After cardioplegia, ischemia/reperfusion injury can induce apoptosis. The aim of this study was to evaluate our ex vivo microperfusion model on human myocardium during simulated cardioplegia (cp) and reperfusion (rep). In addition, the aim was to verify the anti-apoptotic properties of the phosphodiesterase 3 inhibitor milrinone. METHODS: Cardiac biopsies were retrieved from the right auricle of patients undergoing elective CABG prior to induction of cardiopulmonary bypass. Biopsies were exposed to ex vivo conditions with varying periods of cp/rep (30/10, 60/20, 120/40 min). Group I consisted of untreated controls (n=15), Group II of treated controls who had cp/rep (n=15) while Group III had cp/rep+milrinone (n=15). For the detection of apoptosis, anti-activated caspase-3 and PARP-1 cleavage immunostaining were used. RESULTS: The percentage of apoptotic cardiomyocytes in Group I was significantly (P<0.05) lower compared to Group II, revealing a time-dependent increase. In Group III with milrinone treatment, apoptosis was significantly suppressed (P<0.05). CONCLUSIONS: Milrinone significantly suppressed apoptosis in our ex vivo setting. This finding warrants further study aiming to evaluate the potential beneficial effects of milrinone on the suppression of ischemia/reperfusion injury in a clinical setting.


Subject(s)
Apoptosis/drug effects , Cyclic Nucleotide Phosphodiesterases, Type 3/drug effects , Extracorporeal Circulation , Milrinone/pharmacology , Myocardial Reperfusion Injury/prevention & control , Myocardial Reperfusion/adverse effects , Myocardium/pathology , Phosphodiesterase Inhibitors/pharmacology , Aged , Biopsy , Caspase 3/metabolism , Female , Heart Arrest, Induced , Humans , Immunohistochemistry , In Vitro Techniques , Male , Middle Aged , Myocardial Reperfusion Injury/etiology , Myocardial Reperfusion Injury/pathology , Myocardium/enzymology , Perfusion , Pilot Projects , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Time Factors
5.
Thorac Cardiovasc Surg ; 57(5): 304-5, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19629895

ABSTRACT

Cardiac fibromas are rare lesions which occur predominantly in infants and children. In a 2-week-old premature infant with progressive exertional dyspnea, a huge cardiac tumor (5.0 x 4.5 x 5.0 cm) obstructing the right ventricle was diagnosed. Due to tumor progression with resulting obstruction of the right ventricular outflow tract (RVOT), surgery became necessary at 6 months. The tumor was partially resected, creating a crater-like defect, and the resection margins were subsequently plicated. Histological examination confirmed infantile fibroma. The combination of early diagnosis, the time and opportunity for cardiac development and immediate excision once symptoms occur is supposed to improve survival.


Subject(s)
Cardiac Surgical Procedures , Fibroma/surgery , Heart Neoplasms/surgery , Dyspnea/etiology , Dyspnea/surgery , Early Diagnosis , Echocardiography , Fibroma/complications , Fibroma/diagnosis , Gestational Age , Heart Neoplasms/complications , Heart Neoplasms/diagnosis , Heart Ventricles/surgery , Humans , Infant , Infant, Newborn , Infant, Premature , Magnetic Resonance Imaging , Male , Treatment Outcome , Ventricular Outflow Obstruction/etiology , Ventricular Outflow Obstruction/surgery
7.
Eye (Lond) ; 17(5): 593-8, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12855965

ABSTRACT

PURPOSE: To compare systemic arterial blood pressure (BP) and nocturnal hypotension in patients with normal-tension glaucoma (NTG), high-tension glaucoma (HTG), and ocular hypertension. METHODS: Systemic BP was recorded by a portable automated BP monitoring device every 20 min during the day and every 30 min at night in patients with NTG (n=18), HTG (n=22), and ocular hypertension (n=19). Mean systolic, diastolic, and mean arterial BPs were calculated for 24 h, during the day and at night. The mean and maximum nocturnal dip rates were determined for each patient. The number of readings that declined below 90 mmHg for systolic BP and below 60 and 50 mm Hg for diastolic BP was recorded for each group. Statistical significance was set at P<0.05. RESULTS: Minimum, maximum, and mean values of the systolic, diastolic, and mean arterial BPs were not significantly different among groups. There was no difference among groups in the nocturnal dip percentages of systolic and diastolic BPs. The number of systolic BP readings below 90 mmHg was significantly higher in the NTG group compared with the other groups (P<0.001, chi(2) test). CONCLUSION: There may not be any difference among NTG, HTG, and ocular hypertension patients in terms of mean ambulatory BP values. On the other hand, when each individual's ambulatory reading is reviewed, readings may reveal that excessive and repetitive nocturnal drops occur more frequently in some patients with NTG. These hypotensive episodes may be related to the development of glaucomatous damage.


Subject(s)
Blood Pressure/physiology , Ocular Hypertension/physiopathology , Adult , Blood Pressure Monitoring, Ambulatory , Circadian Rhythm/physiology , Female , Glaucoma/physiopathology , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...